RxDoctor Payments Data

Aaron Emmons, MD

Advanced Heart Failure and Transplant Cardiology · Wheat Ridge, CONPI 1275876922

Payments from drug & device makers

What this record shows

This record is dominated by grants: $20,000 of the $21,512 with a category attached, or 93.0%. Medtronic accounts for 93.0% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2020 at $20,000 and has fallen 98.1% since, to $375 in 2025.

$21,512in general payments, 2019–2025

Across 48 payments — averaging $448.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$20K
  • Edwards Lifesciences$354
  • Pfizer$240
  • Boston Scientific$194
  • Cvrx, Inc.$189
  • Abbott$141
  • plus $394 from 10 others

What the payments were for

  • Grants$20,00093%
  • Food & beverage$1,5127%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Coloradoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$135,382
Medicare patients
796
Services billed
2,118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis19$492,915
EliquisApixaban253$332,953
JardianceEmpagliflozin199$274,101
EntrestoSacubitril/Valsartan190$268,604
XareltoRivaroxaban68$93,544
FarxigaDapagliflozin Propanediol40$39,584
Repatha SureclickEvolocumab16$22,823
WegovySemaglutide12$17,429
Metoprolol Succinate352$3,808
Spironolactone374$3,576
Rosuvastatin Calcium242$3,035
Eplerenone18$1,673
Torsemide57$1,552
Losartan Potassium178$1,500
Atorvastatin Calcium180$1,165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$240$825,868272 claims
Boehringer IngelheimJardiance$59$274,101199 claims
NovartisEntresto$23$268,604190 claims
Johnson & JohnsonXarelto$16$93,54468 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Coloradoon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Wheat Ridge

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →